Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Morgan Stanley
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, MarketBeat reports. The firm presently has a $250.00 price objective on the biotechnology company’s stock, up from their previous price objective […]
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Monday, MarketBeat reports. The firm presently has a $250.00 price objective on the biotechnology company’s stock, up from their previous price objective […]
